Matinas Biopharma Holdings Stock Market Value
| MTNB Stock | USD 1.48 0.12 7.50% |
| Symbol | Matinas |
Matinas BioPharma Price To Book Ratio
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Matinas BioPharma. If investors know Matinas will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Matinas BioPharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Matinas BioPharma is measured differently than its book value, which is the value of Matinas that is recorded on the company's balance sheet. Investors also form their own opinion of Matinas BioPharma's value that differs from its market value or its book value, called intrinsic value, which is Matinas BioPharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Matinas BioPharma's market value can be influenced by many factors that don't directly affect Matinas BioPharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Matinas BioPharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Matinas BioPharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Matinas BioPharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Matinas BioPharma 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Matinas BioPharma's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Matinas BioPharma.
| 05/15/2025 |
| 08/13/2025 |
If you would invest 0.00 in Matinas BioPharma on May 15, 2025 and sell it all today you would earn a total of 0.00 from holding Matinas BioPharma Holdings or generate 0.0% return on investment in Matinas BioPharma over 90 days. Matinas BioPharma is related to or competes with Nektar Therapeutics, Passage Bio, Nkarta, Foghorn Therapeutics, VTv Therapeutics, Equillium, and Oragenics. Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development o... More
Matinas BioPharma Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Matinas BioPharma's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Matinas BioPharma Holdings upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 5.44 | |||
| Information Ratio | 0.1622 | |||
| Maximum Drawdown | 33.57 | |||
| Value At Risk | (7.50) | |||
| Potential Upside | 12.99 |
Matinas BioPharma Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Matinas BioPharma's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Matinas BioPharma's standard deviation. In reality, there are many statistical measures that can use Matinas BioPharma historical prices to predict the future Matinas BioPharma's volatility.| Risk Adjusted Performance | 0.1473 | |||
| Jensen Alpha | 1.51 | |||
| Total Risk Alpha | 0.3639 | |||
| Sortino Ratio | 0.2429 | |||
| Treynor Ratio | (1.75) |
Matinas BioPharma Backtested Returns
Matinas BioPharma is abnormally volatile given 3 months investment horizon. Matinas BioPharma has Sharpe Ratio of 0.17, which conveys that the firm had a 0.17 % return per unit of risk over the last 3 months. We were able to interpolate twenty-nine different technical indicators, which can help you to evaluate if expected returns of 1.37% are justified by taking the suggested risk. Use Matinas BioPharma Downside Deviation of 5.44, mean deviation of 5.1, and Risk Adjusted Performance of 0.1473 to evaluate company specific risk that cannot be diversified away. Matinas BioPharma holds a performance score of 13 on a scale of zero to a hundred. The company secures a Beta (Market Risk) of -0.81, which conveys possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning Matinas BioPharma are expected to decrease at a much lower rate. During the bear market, Matinas BioPharma is likely to outperform the market. Use Matinas BioPharma expected short fall, and the relationship between the value at risk and daily balance of power , to analyze future returns on Matinas BioPharma.
Auto-correlation | 0.13 |
Insignificant predictability
Matinas BioPharma Holdings has insignificant predictability. Overlapping area represents the amount of predictability between Matinas BioPharma time series from 15th of May 2025 to 29th of June 2025 and 29th of June 2025 to 13th of August 2025. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Matinas BioPharma price movement. The serial correlation of 0.13 indicates that less than 13.0% of current Matinas BioPharma price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.13 | |
| Spearman Rank Test | 0.1 | |
| Residual Average | 0.0 | |
| Price Variance | 0.02 |
Matinas BioPharma lagged returns against current returns
Autocorrelation, which is Matinas BioPharma stock's lagged correlation, explains the relationship between observations of its time series of returns over different periods of time. The observations are said to be independent if autocorrelation is zero. Autocorrelation is calculated as a function of mean and variance and can have practical application in predicting Matinas BioPharma's stock expected returns. We can calculate the autocorrelation of Matinas BioPharma returns to help us make a trade decision. For example, suppose you find that Matinas BioPharma has exhibited high autocorrelation historically, and you observe that the stock is moving up for the past few days. In that case, you can expect the price movement to match the lagging time series.
Current and Lagged Values |
| Timeline |
Matinas BioPharma regressed lagged prices vs. current prices
Serial correlation can be approximated by using the Durbin-Watson (DW) test. The correlation can be either positive or negative. If Matinas BioPharma stock is displaying a positive serial correlation, investors will expect a positive pattern to continue. However, if Matinas BioPharma stock is observed to have a negative serial correlation, investors will generally project negative sentiment on having a locked-in long position in Matinas BioPharma stock over time.
Current vs Lagged Prices |
| Timeline |
Matinas BioPharma Lagged Returns
When evaluating Matinas BioPharma's market value, investors can use the concept of autocorrelation to see how much of an impact past prices of Matinas BioPharma stock have on its future price. Matinas BioPharma autocorrelation represents the degree of similarity between a given time horizon and a lagged version of the same horizon over the previous time interval. In other words, Matinas BioPharma autocorrelation shows the relationship between Matinas BioPharma stock current value and its past values and can show if there is a momentum factor associated with investing in Matinas BioPharma Holdings.
Regressed Prices |
| Timeline |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Matinas BioPharma offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Matinas BioPharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Matinas Biopharma Holdings Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Matinas Biopharma Holdings Stock:Check out Matinas BioPharma Correlation, Matinas BioPharma Volatility and Matinas BioPharma Alpha and Beta module to complement your research on Matinas BioPharma. You can also try the Bollinger Bands module to use Bollinger Bands indicator to analyze target price for a given investing horizon.
Matinas BioPharma technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.